The BRACAnalysis® test assesses a woman’s risk of developing hereditary breast or ovarian cancer based on detection of mutations in the BRCA1 and BRCA2 genes. This test has become the standard of care in identification of individuals with hereditary breast and ovarian cancer.
COLARIS® testing assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine cancer. COLARIS detects disease-causing mutations in the MLH1, MSH2, MSH6, PMS2 and EPCAM genes which are responsible for the majority of Lynch syndrome related cancers.
COLARIS AP® testing assesses a person’s risk of developing hereditary colorectal polyps and cancer. COLARISAP detects mutations in the APC and MYH genes, which cause adenomatous polyposis colon cancer syndromes, including familial adenomatous polyposis (FAP), attenuated FAP (AFAP), and MYH-associated polyposis (MAP).
MELARIS® testing assesses a person’s risk of developing hereditary melanoma. This test detects inherited mutations in the p16 gene (also called CDKN2A or INK4A), which are associated with hereditary melanoma.
PANEXIA® testing assesses a person’s risk of developing hereditary pancreatic cancer. PANEXIA offers insight about the risk of future hereditary cancers for patients and their families. PANEXIA analyzes the PALB2 and BRCA2 genes, the two genes most commonly mutated in families with hereditary pancreatic cancer.
OnDose® testing evaluates 5-FU exposure for patients undergoing continuous infusion 5-FU chemotherapy. OnDose allows physicians to make a pharmacokinetic determination of the Area Under the Curve (AUC) for each infusion cycle and provides insight to help the physician proactively adjust and optimize dosing to optimize efficacy and reduce toxicity.
PREZEON™ testing assesses loss of PTEN function in cancer patients, which is associated with more aggressive disease progression and poorer survival rate. The PTEN gene is a major tumor suppressor that plays a critical role in cell signaling pathways that are the target of cancer drugs, such as EGFR and mTOR inhibitors.
TheraGuide® 5-FU testing assesses a person’s risk of developing a severe toxic reaction to 5-FU-based chemotherapy. It detects variations in 2 genes, dihydropyrimidine dehydrogenase (DPYD) and thymidylate synthetase (TYMS), that are responsible for a significant portion of serious adverse reactions to 5-FU-based therapy.
Prolaris® testing assesses the prostate cancer aggressiveness in conjunction with other clinical parameters. Prolaris measures the expression level of genes involved with cell cycle progression in tumor specimens to predict disease outcome.